Odonate Therapeutics Inc (NASDAQ:ODT)’s stock price was up 5.2% during trading on Monday . The stock traded as high as $33.87 and last traded at $33.33, approximately 149,710 shares traded hands during trading. An increase of 64% from the average daily volume of 91,531 shares. The stock had previously closed at $31.67.
Several equities analysts have recently commented on ODT shares. ValuEngine downgraded shares of Odonate Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research raised shares of Odonate Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research note on Wednesday, September 25th.
The stock has a market capitalization of $972.16 million, a P/E ratio of -9.16 and a beta of 1.77. The firm’s 50 day moving average price is $28.03 and its 200 day moving average price is $28.86.
Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings data on Wednesday, July 24th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.09. Equities research analysts expect that Odonate Therapeutics Inc will post -4.51 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its position in shares of Odonate Therapeutics by 106.9% during the second quarter. Tower Research Capital LLC TRC now owns 1,703 shares of the company’s stock valued at $63,000 after buying an additional 880 shares during the period. Meeder Asset Management Inc. grew its holdings in Odonate Therapeutics by 198.7% in the second quarter. Meeder Asset Management Inc. now owns 1,574 shares of the company’s stock worth $57,000 after purchasing an additional 1,047 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Odonate Therapeutics by 2.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 55,205 shares of the company’s stock worth $2,026,000 after purchasing an additional 1,150 shares during the period. Chartwell Investment Partners LLC grew its holdings in Odonate Therapeutics by 6.2% in the second quarter. Chartwell Investment Partners LLC now owns 30,543 shares of the company’s stock worth $1,121,000 after purchasing an additional 1,782 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Odonate Therapeutics by 109.8% in the second quarter. Russell Investments Group Ltd. now owns 5,351 shares of the company’s stock worth $196,000 after purchasing an additional 2,800 shares during the period. Institutional investors own 96.52% of the company’s stock.
Odonate Therapeutics Company Profile (NASDAQ:ODT)
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Recommended Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.